Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether shotgun sequencing technology, which can be used to detect donor DNA in recipient plasma, can be used as a rapid, accurate, non-invasive method to detect Acute Cellular Rejection (ACR) after heart transplantation. Currently, all heart transplant recipients undergo invasive heart biopsies to diagnose ACR. Thus, there is an ongoing need to monitor patients for the development of acute and chronic rejection, with the primary goal of non-invasive early detection and treatment to prevent organ damage.

Clinical Trial Description

Previous attempts to develop a non-invasive marker of graft rejection have focused on recipient-specific immune responses, and thus have inherent limitations in both sensitivity and selectivity, especially in distinguishing rejection from infection. The investigators' goal is to use a novel DNA sequencing technology to develop a rapid, inexpensive, and non-invasive method for monitoring organ transplant recipients for graft rejection. The investigators' research is driven by the fact that acute and chronic rejection of thoracic organ transplants remain major causes of patient morbidity and mortality, and require intense resource utilization. The investigators' novel approach is the first to focus on a donor-specific marker of acute rejection. The investigators will use high throughput next generation sequencing to monitor the proportion of cell-free donor DNA to recipient DNA in the recipient's blood stream as a marker of rejection. This approach is enabled by the fact that an organ transplant is also effectively a genome transplant, and by monitoring single nucleotide polymorphisms that are specific to the donor's genome (and are not shared with the recipient's genome) one can measure the relative health of the transplanted organ. The investigators' preliminary studies show that cell-free donor DNA levels in the serum of heart transplant recipients increase prior to diagnosis of acute rejection by endomyocardial biopsy, but remain at stable low levels in the absence of acute rejection. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01985412
Study type	Observational
Source	Stanford University
Contact
Status	Completed
Phase
Start date	March 2010
Completion date	September 29, 2013

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT06309628` - Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
Withdrawn	`NCT02893176` - Macitentan in the Treatment of Organ Rejection After Lung Transplantation	Phase 4
Completed	`NCT02441413` - Transplant Optimization Using Functional Imaging (TROFI)	N/A
Recruiting	`NCT05375149` - Exhaled Breath Particles in Lung Transplantation
Active, not recruiting	`NCT03967340` - PREdiction of Chronic LUng Allograft Dysfunction
Active, not recruiting	`NCT05260372` - Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
Recruiting	`NCT06082037` - A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction	Phase 3
Recruiting	`NCT04714801` - Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation	Phase 1/Phase 2
Active, not recruiting	`NCT05170425` - LAMBDA 002 (Lung Registry) Study
Completed	`NCT02474927` - Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation	Phase 2
Recruiting	`NCT05006742` - Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients	N/A
Recruiting	`NCT02812290` - Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
Not yet recruiting	`NCT03500575` - Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients	N/A
Withdrawn	`NCT03805178` - Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization	Phase 2
Completed	`NCT03359863` - Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction	Phase 2
Active, not recruiting	`NCT03656926` - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)	Phase 3
Completed	`NCT04234919` - Longitudinal Study of Cell Free DNA in Lung Transplant
Recruiting	`NCT04837339` - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation	N/A
Recruiting	`NCT03090581` - Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation.	N/A
Recruiting	`NCT06112951` - A Prospective Randomized Trial of ECP in Subclinical AMR	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection — GTD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms